In a study by Gu, reduced expression of EMX2OS was identified and suggested as a potential prognostic biomarker for poor recurrence-free survival (RFS) in classical papillary thyroid carcinoma (PTC) [26]. Here, EMX2OS is linked to differentiated thyroid carcinoma.